ES2384099T3 - Proteína C para cicatrización de heridas - Google Patents

Proteína C para cicatrización de heridas Download PDF

Info

Publication number
ES2384099T3
ES2384099T3 ES02729651T ES02729651T ES2384099T3 ES 2384099 T3 ES2384099 T3 ES 2384099T3 ES 02729651 T ES02729651 T ES 02729651T ES 02729651 T ES02729651 T ES 02729651T ES 2384099 T3 ES2384099 T3 ES 2384099T3
Authority
ES
Spain
Prior art keywords
pca
protein
wound
agent
wounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02729651T
Other languages
English (en)
Spanish (es)
Inventor
Christopher John Jackson
Philip Neil Sambrook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sydney
Original Assignee
University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR5637A external-priority patent/AUPR563701A0/en
Priority claimed from AUPS1433A external-priority patent/AUPS143302A0/en
Application filed by University of Sydney filed Critical University of Sydney
Application granted granted Critical
Publication of ES2384099T3 publication Critical patent/ES2384099T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES02729651T 2001-06-13 2002-06-11 Proteína C para cicatrización de heridas Expired - Lifetime ES2384099T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR5637A AUPR563701A0 (en) 2001-06-13 2001-06-13 Treatment and composition for wound healing
AUPR015637 2001-06-13
AUPS1433A AUPS143302A0 (en) 2002-04-02 2002-04-02 Treatment and composition for wound healing
AUPR021433 2002-04-02
PCT/AU2002/000751 WO2002100445A1 (en) 2001-06-13 2002-06-11 Treatment and composition for wound healing

Publications (1)

Publication Number Publication Date
ES2384099T3 true ES2384099T3 (es) 2012-06-29

Family

ID=25646727

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02729651T Expired - Lifetime ES2384099T3 (es) 2001-06-13 2002-06-11 Proteína C para cicatrización de heridas

Country Status (8)

Country Link
US (3) US20040176288A1 (enExample)
EP (1) EP1404412B1 (enExample)
JP (1) JP4351041B2 (enExample)
AT (1) ATE550073T1 (enExample)
AU (1) AU2002302192B2 (enExample)
CA (1) CA2450240A1 (enExample)
ES (1) ES2384099T3 (enExample)
WO (1) WO2002100445A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2298338T1 (sl) 2002-09-16 2012-11-30 Agennix Inc Laktoferinski sestavki in postopki za zdravljenjekožnih ran
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US20080293631A1 (en) * 2005-01-07 2008-11-27 Christopher John Jackson Treatment for Autoimmune and Inflammatory Conditions
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
BRPI0613227A2 (pt) * 2005-06-09 2011-01-04 Chiang Chuan Chi uma composição para cicatrização de ferida e uso desta
WO2007075853A2 (en) * 2005-12-20 2007-07-05 Swiss-American Products, Inc. Protease compositions for the treatment of damaged tissue
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
GB2457965B8 (en) * 2008-07-01 2011-02-16 Renovo Ltd Methods and systems for determining efficacy of medicaments.
US20130259854A1 (en) * 2012-04-02 2013-10-03 Saint Louis University, A Non-Profit Organization Methods and compositions for reducing the incidence of post-surgical adhesions
CN104394883B (zh) * 2012-07-04 2017-05-31 悉尼大学 炎性皮肤病症的治疗
EP3137102B1 (en) * 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
US20170035862A1 (en) * 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
TR202021285A1 (tr) * 2020-12-22 2022-07-21 Univ Yeditepe Yara skarinin önlenmesi̇ ve tedavi̇si̇nde kullanilmak üzere erbium borat i̇çeren formülasyon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
EP0651655A4 (en) * 1992-07-24 1996-05-29 Oklahoma Med Res Found REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION
US5583102A (en) * 1993-12-03 1996-12-10 University Of Iowa Research Foundation Human thrombomodulin in wound healing
AU2467395A (en) * 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
JP3802104B2 (ja) 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP3578627B2 (ja) * 1998-05-15 2004-10-20 株式会社ホギメディカル 創傷患部の治癒を促進する組織シーラント
CA2358492A1 (en) 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
ES2242740T3 (es) * 2000-03-28 2005-11-16 Eli Lilly And Company Proteina c activada para el tratamiento de pancreatitis.
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C

Also Published As

Publication number Publication date
EP1404412A1 (en) 2004-04-07
US8728512B2 (en) 2014-05-20
CA2450240A1 (en) 2002-12-19
EP1404412A4 (en) 2006-03-01
EP1404412B1 (en) 2012-03-21
ATE550073T1 (de) 2012-04-15
US20040176288A1 (en) 2004-09-09
US20140219991A1 (en) 2014-08-07
JP2004532892A (ja) 2004-10-28
AU2002302192B2 (en) 2007-08-16
US20130280234A1 (en) 2013-10-24
WO2002100445A1 (en) 2002-12-19
JP4351041B2 (ja) 2009-10-28
WO2002100445A8 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
US8728512B2 (en) Treatment and composition for wound healing
JP2004532892A6 (ja) 傷治癒のための処置および組成物
AU2002302192A1 (en) Treatment and composition for wound healing
Scott et al. 051 Topical Oxygen Alters Angiogenesis‐Related Growth Factor Expression in Chronic Diabetic Foot Ulcers
Stechmiller et al. 052 Effect of Negative Pressure Wound Therapy on the Expression of TNF‐α, IL‐1β, MMP‐2, MMP‐3, and TIMP‐1 in Wound Fluid of Adults with Pressure Ulcers
Mooney et al. 031 Mechanical Characteristics of Fibroblast–Fibrin Constructs: Effect of Fibrinogen and Thrombin Concentration
Monroe et al. 075 Effect of Polyhydrated Ionogen (PHI) on Viability and Matrix Metalloproteinase Levels in Medium of Cultured Cells
Janis et al. 071 Connective Tissue Growth Factor (CTGF) Content and Bioactivity of Small Intestinal Submucosa (SIS)
Man et al. 065 Blockade of Rage with Lentiviral Gene Therapy Accelerates Healing in Diabetic Wounds Over Time
Huemer et al. 022 Extracorporal Shock Wave is More Effective than Gene Therapy with TGF‐Beta to Reduce Ischemic Necrosis in a Rat Epigastric Skin Flap Model
Agarwal et al. 009 Differential Phenotypical Expression of Healing vs. Normal Fibroblasts
Krötzsch et al. 055 A Comparative Evaluation of Maltodextrin/Ascorbic Acid Vs. Standard Care for the Treatment of Venous Leg Ulcers
Pirayesh et al. 054 The Efficacy of PolyHydrated Ionogens in Achieving Stable Wound Closure in Recalcitrant Diabetic Foot Ulcers: A Multicenter Phase 1 Pilot Study
Ho et al. 072 Wound Healing Properties of Reconstituted Freeze‐Dried Platelets
Higgins 087 PAI‐1 Gene Expression in Wound‐Edge Keratinocytes is Upstream Stimulatory Factor‐Dependent and Required for Cell Migration
Sandulache et al. 048 Interleukin‐1β Regulates the Secretion of but not Expression of Receptors for Prostaglandin E2
Guthrie 050 Amplification of the Hypoxic Wound Signal by Treprostinil Sodium (Remodulin®) as Measured by PeriWound Tcpo2 and Laser Doppler Signals
Yao et al. 056 Activation of Sterol Regulatory Element‐Binding Proteins ((SREBPs) is Critical in IL‐8‐Induced Angigiogenesi
Ducale et al. 030 Inhibition of Mitogen Activated Kinase‐Mediated Hyaluronan Expression by Glucocorticoids
Bodnar et al. 057 Activation of CXCR 3 Inhibits Endothelial Tube Formation Through the Modulation of M‐Calpain
Kryger et al. 040 The Temporal Expression of the TGF‐Beta Pathway in the Rabbit Ear Model of Hypertrophic Scarring
Said et al. 023 HRE‐Luciferase Transfection Quantifies Tissue Level Ischemia in a Rabbit Ear Wound Model
Childress et al. 053 Nitric Oxide Metabolites in Wound Fluid of Adults with Pressure Ulcers on VAC® Therapy
Okwueze et al. 042 Role of Erbb3 and Epidermal Growth Factor‐Like Ligands on Wound Healing
Lam et al. 019 Stratifin‐Induced MMP‐1 in Fibroblast is Mediated by c‐Fos and P38 MAPK Activation